CNS indication/ Endpoint prioritization
Less than 1 min read
Scroll
The challenge
- A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize indications for ongoing clinical development
Our solution
- Through extensive primary/ secondary market research and literature review, we ranked each potential indication across multiple dimensions including epidemiology, burden of persistent unmet clinical need/ quality-of-life effects, complexity of standard clinical endpoints and symptom scores, likelihood of improvement, and on-market and pipeline competitive intensity
The results
- Highest ranking diseases (and respective endpoints) were prioritized by the Clinical Development and Medical Affairs teams for incorporation into the ongoing clinical trial program
Jump to a slide with the slide dots.
Medical Affairs omnichannel platform
A large biopharma client objective aimed to optimize its omnichannel (OC) approach for HCP and patient Medical Education...
Read moreRare respiratory claims data analysis
A top biopharma client wanted to understand diagnosis and treatment patterns for a rare respiratory disease only recently associated as a sequela....
Read moreRare disease research consortium guidance on AI diagnostic tools
A rare disease research consortium sought to identify barriers to adoption of AI-enabled, point-of-care diagnostic decision support tools..
Read more